Novo Nordisk Issues Mixed 2026 Outlook with Adjusted Sales/Profit Decline Amidst Pricing Pressures
NVO sits 17% above its 52-week low of $43.08.
Summary
Novo Nordisk provided its 2026 financial outlook, projecting a decline in adjusted sales and operating profit due to pricing pressures and competition, despite a significant one-time $4.2 billion rebate reversal boosting non-adjusted figures.
Key Events · Earnings and Guidance · NVO
-
2026 Outlook Released
Novo Nordisk provided its full-year 2026 sales and operating profit outlook, following 10% sales growth and 6% operating profit growth in 2025.
-
New Adjusted Metrics Introduced
The company will now report 'adjusted sales growth' and 'adjusted operating profit growth' to exclude exceptional and non-recurring items, enhancing transparency of underlying performance.
-
Adjusted Outlook Projects Decline
Adjusted sales and operating profit are projected to decline by -5% to -13% at constant exchange rates for 2026.
-
Significant One-Time Gain
A $4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program will positively impact non-adjusted 2026 results, leading to a non-adjusted operating profit growth mid-point of 11%.
Analysis · NVO · Life Sciences
Novo Nordisk's 2026 outlook presents a complex picture for investors. While the company anticipates an 11% increase in non-adjusted operating profit, this is largely driven by a one-time $4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program. More critically, the newly introduced "adjusted" metrics, which exclude such non-recurring items, project a significant decline of -5% to -13% for both sales and operating profit. This adjusted outlook highlights underlying challenges including lower realized prices due to the MFN agreement in the US, intensifying competition in the GLP-1 market, and loss of exclusivity for semaglutide in certain international markets. Investors will need to carefully consider these adjusted figures as a more accurate reflection of the company's ongoing operational performance, despite continued GLP-1 market expansion and new product launches like the Wegovy pill.
At the time of this filing, NVO was trading at $50.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $260.8B. The 52-week trading range was $43.08 to $93.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.